As detailed above, RANK is expressed in a variety of immune cells from macrophages to DCs, NKs, T cells, and myeloid-derived suppressor cells (MDSCs), and so by blocking the RANK–RANKL pathway, Denosumab may enhance the activity of these immune cells in the tumor microenvironment (TME) or indeed in the case of Tregs or MDSCs, reducing their immune-suppressive function. The gene discussed is TNFSF11; the disease is neoplasm.